Order Article Reprints

Wang J-H, Chen Y-Y, Kee K-M, Wang C-C, Tsai M-C, Kuo Y-H, Hung C-H, Li W-F, Lai H-L, Chen Y-H. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers. 2022; 14(2):343. https://doi.org/10.3390/cancers14020343

Wang, Jing-Houng, Yen-Yang Chen, Kwong-Ming Kee, Chih-Chi Wang, Ming-Chao Tsai, Yuan-Hung Kuo, Chao-Hung Hung, Wei-Feng Li, Hsiang-Lan Lai, and Yen-Hao Chen. 2022. "The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab" Cancers 14, no. 2: 343. https://doi.org/10.3390/cancers14020343

Wang, J.-H., Chen, Y.-Y., Kee, K.-M., Wang, C.-C., Tsai, M.-C., Kuo, Y.-H., Hung, C.-H., Li, W.-F., Lai, H.-L., & Chen, Y.-H. (2022). The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Cancers, 14(2), 343. https://doi.org/10.3390/cancers14020343